MindWalk Holdings Corp.

NASDAQ:HYFT

Biotechnology

Healthcare
$1.08 +0.33%

+$0.01 today

Market cap
$50.88M
Beta
0.82
P/E (TTM)
-8.1
EPS (TTM)
-$0.26
52W Low $0.82High $3.25

Volume 0.20M

Average 0.32M

HYFT Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

MindWalk Holdings Corp.NASDAQ: HYFT

Gross Profit · Q3 FY2026 · quarter ended Jan 2026

Gross profit dips below year-ago levels

Q3 FY2026 gross profit of CA$2.42M fell 26.4% year over year, behind the +26.1% change in trailing-twelve-month gross profit. Sequentially, it fell 8.9% from the prior quarter. Over 3 fiscal years it compounded at +7.2% a year.

Context

  • Gross profit amounted to 55.3% of revenue in FY2025, up 6.1 pp from a year earlier.
  • Gross profit increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -26.4% toward the trailing-twelve-month pace of +26.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJan 2026
CA$2.42M-8.9% QoQ
Last fiscal yearApr 2025
CA$13.55M+12.4% YoY
LTMJan 2026
CA$11.07M+26.1% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-26.4%——
1 year+12.4%——
3-year CAGR+7.2%——
5-year CAGR——
10-year CAGR——

Gross Profit history

CAD · from the income statement

Latest · FY2025
13.55M CAD
Year-over-year change
+12.4%
4-year CAGR
+4.1%

Gross Profit vs competitors

How HYFT compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +26.1% is the 4th highest of 8, against a peer median of +20.7%.
  • Gross profit amounts to 60.3% of revenue for HYFT, versus a peer median of 129.1%.
HYFT Competitors
Gross Profit for HYFT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FBIOFortress Biotech, Inc.LTM Mar 2026$42.68M USD+20.7%-2.0%64.5%
HYFTMindWalk Holdings Corp.LTM Jan 2026CA$11.07M CAD+26.1%+7.2%60.3%
CAMPCAMP4 Therapeutics CorporationLTM Mar 2026$3M USD+337.0%—76.2%
GUTSFractyl Health, Inc. Common StockLTM Mar 2026$0 USD-100.0%——
BYSIBeyondSpring Inc.LTM Mar 2026-$19K USD+96.2%——
ALXOALX Oncology Holdings Inc.LTM Mar 2026-$150K USD+31.8%——
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026-$211K USD———
CLNNClene Inc.LTM Mar 2026-$244K USD-188.4%-29.4%182.1%
ATYRaTyr Pharma, Inc.LTM Mar 2026-$22.33M USD-82.6%—11754.7%
Peer median (excluding HYFT) —+20.7%-15.7%129.1%

Competitors are the stored peer set for HYFT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Apr 2021
FY2022
Apr 2022
FY2023
Apr 2023
FY2024
Apr 2024
FY2025
Apr 2025
Revenue17.91M19.36M20.67M24.52M24.52M
Cost of Revenue6.37M8.38M9.1M12.47M10.97M
Gross Profit11.54M10.98M11.56M12.05M13.55M
Gross Margin64.4%56.7%56.0%49.2%55.3%
Research & Development1.97M7.66M14.1M4.04M4.94M
Selling, General & Admin13.27M18.06M18.99M19.14M19.03M
Operating Expenses15.71M27.66M37.17M25.82M25.74M
Depreciation & Amortization3.71M3.77M6.69M5.74M5.12M
EBITDA(1.42M)(11.99M)(21.04M)(22.95M)(28.86M)
EBITDA Margin-7.9%-61.9%-101.8%-93.6%-117.7%
Operating Income(4.18M)(16.67M)(25.61M)(13.76M)(12.2M)
Operating Margin-23.3%-86.1%-123.9%-56.1%-49.7%
Interest Income265.01K279K122K23K0
Interest Expense602.37K85K30K19K9.91K
Other Income / Expenses(1.82M)825K(2.14M)(14.94M)(22.07M)
Income Before Tax(6M)(15.85M)(27.75M)(28.7M)(34.27M)
Pre-Tax Margin-33.5%-81.8%-134.3%-117.1%-139.8%
Income Tax Expense1.35M861K(1.19M)(2.59M)(4.03M)
Net Income(7.34M)(16.71M)(26.56M)(26.12M)(30.23M)
Net Margin-41.0%-86.3%-128.5%-106.5%-123.3%
EPS (Basic)(0.45)(0.87)(1.07)(1.03)(0.90)
EPS (Diluted)(0.45)(0.87)(1.07)(1.03)(0.90)
Weighted Avg Shares16.47M19.69M24.9M25.64M33.39M
Weighted Avg Shares (Diluted)16.47M19.69M24.9M25.64M33.39M

MindWalk Holdings Corp.

NASDAQ:HYFT

Intrinsic Alpha fair value

Locked

Current Price

$1.08

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.